SOURCE: Market Pulse

December 09, 2005 08:30 ET

Market Pulse Breaking News Alert for Friday, December 9, 2005: XKEM -- Xechem Expands Its Arsenal for Treating Sickle Cell Disease; Licenses New Anti-Sickling Agent From Virginia Commonwealth


NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- December 9, 2005 -- Market Pulse News Alert for this AM, Stocks to Watch are: Xechem International, Inc. (OTC BB: XKEM), Analytical Surveys, Inc. (NASDAQ: ANLT), Sycamore Networks Inc. (NASDAQ: SCMR) and Sirius Satellite Radio Inc. (NASDAQ: SIRI).

Investors need to be watching Xechem International, Inc. (OTC BB: XKEM) this AM! Xechem is a biopharmaceutical company engaged in the research, development, and limited production of niche generic and proprietary drugs from natural sources. The company's principal product under development is NICOSAN™/HEMOXIN™, a phytopharmaceutical product that has shown efficacy in the treatment of Sickle Cell Disease. Xechem is working hard to bring NICOSAN™ / HEMOXIN™ to market initially in Nigeria and subsequently in the United States and other countries. There are approximately 4,000,000 people afflicted with Sickle Cell Disease in Nigeria alone. Xechem recently announced that its wholly owned subsidiary, Xechem UK Ltd., received Orphan Drug designation from the European Medicine Evaluation Agency (EMEA) for NICOSAN™/HEMOXIN™. The designation covers all 25 countries that comprise the European Union. The company also applies its proprietary extraction, isolation, and purification technology to the production and manufacture of Paclitaxel, which is an anti-cancer compound used for the treatment of ovarian, breast, small cell lung cancers, and AIDS related kaposi sarcomas. XKEM is poised to become a significant player in the biopharmaceutical industry. XKEM just had excellent news out in a press release before today's opening bell announcing that it has acquired the exclusive, worldwide licensing rights to a new five-membered heterocyclic anti-sickling compound from Virginia Commonwealth University (VCU), Richmond, VA! Investors should be watching this one closely!

Xechem International, Inc. (OTC BB: XKEM) announced today that it has acquired the exclusive, worldwide licensing rights to a new five-membered heterocyclic anti-sickling compound from Virginia Commonwealth University (VCU), Richmond, VA. Early research has shown this anti-sickling agent to be a highly effective and relatively non-toxic treatment for sickle cell disease (SCD). The new compound further expands Xechem's existing portfolio of products to be used in the fight against Sickle Cell Disease.

Previously, Xechem International successfully acquired the exclusive worldwide license from the National Institute for Pharmaceutical Research and Development ("NIPRD"), Ministry of Health, Government of Nigeria, for the manufacture, marketing and distribution of NICOSAN™/HEMOXIN™, an all natural, phyto-pharmaceutical product that has also shown enormous promise for SCD. Both the United States Food and Drug Administration (FDA) and the European Union's regulatory body have already granted to Xechem "Orphan Drug" status for NICOSAN™/HEMOXIN™, and the Company is currently in the process of preparing an Investigational New Drug (IND) Application for submission to the FDA and applicable EU agencies.

According to Xechem's Chairman and CEO, Dr. Ramesh C. Pandey, "We know of no existing non-toxic medicines available anywhere in the world for the effective treatment of Sickle Cell Disease. Between our existing product, NICOSAN™/HEMOXIN™, a non-toxic product that has shown excellent results in Phase IIA and Phase IIB clinical trials in Nigeria, and this promising new heterocyclic pharmaceutical agent being developed in collaboration with VCU, Xechem will be in a truly unique position to offer viable and efficacious treatments to patients suffering with this painful and debilitating condition."

Professor Don Abraham of VCU says that "the five membered heterocyclic compound (5-HMF) is the best potential antisickling agent in 30 years research to be discovered by our research group. 5-HMF not only is a natural product with very little if any toxicity, it has a high affinity for hemoglobin and was very active in genetically modified mice as shown by our colleagues, Dr. Osheiza Abdulmalik and Professor Toshio Asakura, the Director of the NHLBI Sickle Cell Disease Reference Laboratory at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania. A number of us, especially my very close colleagues at VCU, Professors Martin Safo and Gajanan Joshi, have spent most of our lives searching for a sickle cell drug and we are hoping that this quest is finally achieved."

Sickle Cell Disease is a genetic blood disorder caused by an abnormality in the hemoglobin molecule. Patients with this disease often produce stiff, abnormally shaped cells that do not flow freely through blood vessels, creating clogs in the vessels, which in turn cut off the flow of normal hemoglobin and oxygen to the body. In Nigeria alone, more than 25% of the population are carriers of the SCD trait and over 4.5 million Nigerians (~5% of the population) are actually afflicted with the disease. Approximately 12 million people, mostly in sub-Saharan Africa, are believed to suffer from this disease worldwide.

About Xechem

Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease (SCD), antimalarial and antibacterial products from natural sources, including microbial and marine organisms. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its primary focus is on the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases. Its primary attention and resources are currently being directed toward the development and commercial launch of NICOSAN™/HEMOXIN™, which has shown efficacy in the treatment of SCD.

About VCU and the VCU Medical Center

Located on two downtown campuses in Richmond, VA, Virginia Commonwealth University is ranked nationally by the Carnegie Foundation as a top research institution and enrolls more than 28,500 students in over 181 certificate, undergraduate, graduate, professional and doctoral programs in the arts, sciences and humanities in 15 schools and one college. Forty of the University's programs are unique in Virginia, and 20 graduate and professional programs have been ranked by U.S. News & World Report as among the best of their kind. MCV Hospitals, clinics and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the leading academic medical centers in the country. For more, see

Stocks in the news and acting well as of late include: Analytical Surveys, Inc. (NASDAQ: ANLT), Sycamore Networks Inc. (NASDAQ: SCMR) and Sirius Satellite Radio Inc. (NASDAQ: SIRI).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP acquired five million free trading shares of Xechem International, Inc., in a private transaction from a third party shareholder of the company for a total purchase price of fifty thousand dollars. To date, MP has sold zero shares of stock in Xechem International, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information